| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |